Evidence map›Paper›PMID 36344859›Full record

ArticleJournal of immigrant and minority health2023

Assessing Unique Risk Factors for COVID-19 Complications Among Cancer Patients: A Multi-ethnic Cohort Study.

Hala T Borno, Mi-Ok Kim, Irina Tolstykh, Amy Lin, Julian C Hong, Sasha Yousefi, Sylvia Zhang, Rana R McKay, Olivier Harismendy, Pedram Razavi and 7 more

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immigrant and minority health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 77% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 0 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Hala T BornoDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, USA. hala.borno@ucsf.edu.ORCID http://orcid.org/0000-0002-4357-9759
Mi-Ok KimHelen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Irina TolstykhDepartment of Epidemiology and Biostatistics, University of California, San Francisco, USA.
Amy LinDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, USA.
Julian C HongHelen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Sasha YousefiDepartment of Radiation Oncology, University of California, San Francisco, USA.
Sylvia ZhangHelen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Rana R McKayDepartment of Medicine, University of California, San Diego, USA.
Olivier HarismendyDepartment of Medicine, University of California, San Diego, USA.
Pedram RazaviDepartment of Medicine, University of California, San Diego, USA.
Pelin CinarDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, USA.
Hope RugoDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, USA.
Vadim S KoshkinDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, USA.
Maya RabowCollege of Science, Northeastern University, Boston, MA, USA.
Christine WangHelen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Adina BaileyDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, USA.
Eric J SmallDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, USA.
University of California, San Francisco · USUniversity of California San Diego · USUCSF Helen Diller Family Comprehensive Cancer Center · USNortheastern University · US

Funding

University of California (Research Grants Program Office, RGPO) Emergency COVID-19 Funding R00RG3155
6 · The paper itself

Abstract

A myriad of organ-specific complications have been observed with COVID-19. While racial/ethnic minorities have been disproportionately burdened by this disease, our understanding of the unique risk factors for complications among a diverse population of cancer patients remains limited. This is a multi-institutional, multi-ethnic cohort study evaluating COVID-19 complications among cancer patients. Patients with an invasive cancer diagnosis and confirmed SARS-CoV-2 infection were identified from March to November 2020. Demographic and clinical data were obtained and a multivariate logistic regression was employed to evaluate the impact of demographic and clinical factors on COVID-19 complications. The study endpoints were evaluated independently and included any complication, sepsis, pulmonary complications and cardiac complications. A total of 303 patients were evaluated, of whom 48% were male, 79% had solid tumors, and 42% were Hispanic/Latinx (Hispanic). Malignant hematologic cancers were associated with a higher risk of sepsis (OR 3.93 (95% CI 1.58-9.81)). Male patients had a higher risk of sepsis (OR 4.42 (95% CI 1.63-11.96)) and cardiac complications (OR 2.02 (95% CI 1.05-3.89)). Hispanic patients had a higher odds of any complication (OR 2.31 (95% CI 1.18-4.51)) and other race was associated with a higher odds of cardiac complications (OR 2.41 (95% CI 1.01-5.73)). Clinically, fever, cough, and ≥2 co-morbidities were independently significantly associated with any complication. This analysis evaluated covariates that can significantly predict a myriad of complications among a multi-ethnic cohort of cancer patients. The conclusions drawn from this analysis elucidate a mechanistic understanding of differential illness severity from COVID-19.

Indexed as

COVID-19NeoplasmsCohort StudiesFemaleHispanic or LatinoHumansMaleRisk FactorsSARS-CoV-2White PeopleCancerCOVID-19Racial/ethnic minorities

Identifiers

PMID36344859
PMCPMC9640901
OpenAlexW4308408782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.